Streetbeat News

OPTHF

Optimi Health Corp

https://optimihealth.ca/

Industry

Pharmaceutical Preparation Manufacturing

Open

0.13

Mkt cap

12M

Volume

13K

High

0.13

P/E Ratio

-2.40

52-wk high

0.38

Low

0.12

Div yield

N/A

52-wk low

0.10

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

Optimi Health (OTCQX:OPTHF) has received approval from Health Canada to supply MDMA and psilocybin drugs to the country's Special Access Program (SAP). The company has also secured CA$1M in private financing through a non-dilutive debt financing agreement. The loan, bearing a 7.5% annual interest rate, is secured against the company's assets and will be fully repaid by August 29, 2026.

Portfolio Pulse from Lara Goldstein

September 08, 2023 | 3:15 pm

The American Psychedelic Practitioners Association and BrainFutures have published the first-ever professional practice guidelines for psychedelic-assisted therapy. Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has finalized its clinical trial design for a phase 2 DMT stroke study. Atai Life Sciences, MindMed, and COMPASS Pathways have reported their Q2 2023 financial results. AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.

Portfolio Pulse from Lara Goldstein

August 14, 2023 | 1:47 pm

Optimi Health Corp. (OTCQX:OPTHF) has completed its proprietary natural psilocybin extraction process and filed a U.S. provisional patent application. Red Light Holland Corp. (OTCQB:TRUFF) received approval to further manufacturing plans for natural psilocybin microdosing capsules. MGC Pharmaceuticals Ltd (OTC:MGCLF) has gained approval for its first import of psilocybin mushrooms to Slovenia for research purposes.

Portfolio Pulse from Lara Goldstein

August 04, 2023 | 10:37 am

A bipartisan bill has created a $75 million research grant program for the potential treatment of mental health conditions in active duty military members. The Multidisciplinary Association for Psychedelic Studies (MAPS) announced its final agenda for its upcoming event, which will include information on two recently-identified lead compounds. Psychedelics were featured on Anderson Cooper’s CNN show. Several companies, including Silo Pharma, Clearmind, and SciSparc, are developing treatments using psychedelics. The AdvisorShares Psychedelics ETF (PSIL) showed an uptrend.

Portfolio Pulse from Lara Goldstein

July 03, 2023 | 9:01 pm

Numinus Wellness (OTC:NUMIF) will utilize Optimi Health’s (OTC:OPTHF) GMP-compliant MDMA for a therapist-experiential training program in Canada, supported by MAPS. PharmAla Biotech Holdings (OTC:PMBHF) has received a permit to export its GMP-compliant MDMA LaNeo to the University of Sydney.

Portfolio Pulse from Lara Goldstein

June 20, 2023 | 12:43 pm

Terran Biosciences discovers new psilocybin compounds, MindMed's LSD study for anxiety treatment enrolls and doses 100 participants, and PharmAla receives Health Canada's approval for MDMA treatment. UK Parliament debates accelerating psychedelics research and psilocybin rescheduling.

Portfolio Pulse from Lara Goldstein

May 23, 2023 | 11:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.